Tamsulosin With or Without Tadalafil for a Trial Without Catheter After Acute Urinary Retention
Official title: Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial
Run by Beni-Suef University · NCT07654413 · Data updated 2026-11-12
This study tests whether adding tadalafil to tamsulosin helps men with a first episode of acute urinary retention due to enlarged prostate pass urine without needing a catheter.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 320 (estimated) |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Banī Suwayf, Beni Suweif Governorate) |
| Status | Recruiting |
| Started | June 8, 2026 |
| Main results expected | November 2027 |
| Study ends | December 2027 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07654413 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 50+ with a first episode of spontaneous painful acute urinary retention due to presumed BPH, who had successful catheter drainage and meet all eligibility criteria.
✕Probably not a fit
Patients who do not respond to the trial medications or who have contraindications or non-BPH causes of retention may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 4, randomized trial compares tamsulosin alone versus tamsulosin plus tadalafil in men 50 and older who have had acute urinary retention due to benign prostatic obstruction. After initial catheter drainage, participants start their study medications within 24 hours and attempt to void without a catheter by day 7; a second trial without catheter may occur on day 14 if the first attempt fails. The primary outcome is catheter-free success by day 14, with follow-up for recurrent retention. The study is conducted at Beni-Suef University Hospital in Egypt and uses a tadalafil/placebo control to determine if combination therapy improves TWOC outcomes.
Why it matters
Potential benefit: If successful, treatment could increase the chances of avoiding long-term catheter use after acute urinary retention.
How similar studies have gone: Prior studies in BPH-related voiding symptoms have explored combination therapies, but this exact TWOC-focused approach is relatively novel and has limited prior success data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patient aged 50 years or older. * First episode of spontaneous painful acute urinary retention. * Successful urethral catheterization at presentation. * Drained urine volume at presentation of at least 300 mL. * Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and/or ultrasound evidence of enlarged prostate. * Ability to provide written informed consent. Exclusion Criteria: * Previous episode of acute urinary retention. * Chronic painless urinary retention phenotype. * Active urinary tract infection or sepsis. * Gross hematuria with clot retention. * Suspected or known urethral stricture. * Neurogenic bladder or major neurologic disease affecting voiding. * History of prostate cancer or bladder cancer. * Previous prostate surgery. * Current use of nitrates or guanylate cyclase stimulators. * Contraindication to tadalafil or tamsulosin. * Severe hypotension or unstable cardiovascular disease. * Severe renal impairment. * Severe hepatic impairment. * Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.
Where it's running
-
Department of Urology- Beni-Suef University Hospitals
Banī Suwayf, Beni Suweif Governorate, Egypt Recruiting
Study contacts
- Study coordinator: Hany F Badawy, MD
- Email: HANYFATHY86@GMAIL.COM
- Phone: +201149525028
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tamsulosin dose change or switch to silodosin before catheter removal in men with BPH-related acute urinary retention
This trial tests whether continuing tamsulosin, increasing its dose, or switching to silodosin helps men with BPH-related acute urinary retention go without a catheter after seven days.
-
Ejaculation-Preserving Bipolar Prostate Enucleation for BPH
This randomized trial tests whether a modified ejaculation-preserving bipolar TUEP can maintain ejaculation while still relieving urinary symptoms in sexually active men with BPH who didn’t improve with meds.
-
Sonablate HIFU Registry for Prostate Cancer and BPH
This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.
-
Tamsulosin alone vs. tamsulosin with tadalafil for troublesome urinary symptoms from enlarged prostate
This study tests whether adding tadalafil to tamsulosin helps men with BPH see better urinary symptoms and quality of life, using two tadalafil doses over 12 weeks.
-
MRI-DTI look at the urethral sphincter ring and prostate base shape
This imaging study tests how the male urethral internal sphincter ring appears on MRI-DTI and how it relates to prostate base morphology in men undergoing clinically indicated MRI.
-
Water Vapor Therapy vs Ejaculation-Sparing Enucleation for Benign Prostatic Hyperplasia
This study tests whether Water Vapor Thermal Therapy (Rezum) or an ejaculation-sparing enucleation procedure better helps sexually active men with bothersome BPH symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.